NKTR
What one share of Nektar Therapeutics holds
Pharmaceutical Preparations
Nektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes.
Nektar Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.25 |
|---|---|
| Profit | −$6.47 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$9.63 |
| Cash and investments | $1.93 |
| Book value | $44.32 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $17.78 | −$16.50 | $0.69 | −$13.26 | — | $8.63 |
| 2017 | $29.60 | −$9.30 | $0.93 | −$8.67 | — | $8.26 |
| 2018 | $99.38 | $56.74 | $1.19 | $58.63 | — | $148.47 |
| 2019 | $9.82 | −$37.77 | $2.25 | −$30.43 | — | $119.43 |
| 2020 | $12.84 | −$37.33 | $0.61 | −$26.92 | — | $89.73 |
| 2021 | $8.34 | −$42.87 | $1.23 | −$35.00 | — | $54.96 |
| 2022 | $7.38 | −$29.51 | $0.46 | −$24.82 | — | $29.17 |
| 2023 | $7.11 | −$21.79 | $0.07 | −$15.27 | — | $10.27 |
| 2024 | $7.18 | −$8.68 | $0.11 | −$12.92 | — | $4.90 |
| 2025 | $3.27 | −$9.73 | $0.01 | −$12.37 | — | $4.41 |